Article Text

Download PDFPDF

EPV149/#132 Performance characteristics of brief family history questionnaire to screen for lynch syndrome in women with newly diagnosed ovarian cancers
  1. RS Kim1,
  2. A Tone1,
  3. R Kim2,
  4. M Cesari3,
  5. L Eiriksson4,
  6. T Hart5,
  7. A Lytwyn6,
  8. M Maganti7,
  9. M Bernardini1,
  10. A Oza2,
  11. B Djordjevic3,
  12. J Lerner-Ellis3,
  13. E Van De Laar1,
  14. D Vicus8,
  15. A Pollett3 and
  16. S Ferguson1
  1. 1Princess Margaret Cancer Centre/University of Health Network/Sinai Health Systems, Gynecologic Oncology, Toronto, Canada
  2. 2Princess Margaret Cancer Centre/University of Health Network/Sinai Health Systems, Medical Oncology and Hematology, Toronto, Canada
  3. 3University of Toronto, Laboratory Medicine and Pathobiology, Toronto, Canada
  4. 4Juravinski Cancer Centre, McMaster University, Gynecologic Oncology, Hamilton, Canada
  5. 5Ryerson University, Psychology, Toronto, Canada
  6. 6McMaster University, Pathology and Molecular Medicine, Hamilton, Canada
  7. 7Princess Margaret Cancer Centre, Biostatistics, Toronto, Canada
  8. 8Sunnybrook Health Sciences Centre, Gynecologic Oncology, Toronto, Canada


Objectives Ovarian cancer (OC) is the third most common Lynch syndrome (LS)-associated cancer in women but there is no established screening strategy to identify LS in this population. We have previously validated the 4-item brief Family History Questionnaire (bFHQ) in endometrial cancers. The objective of this study was to assess whether bFHQ can be used as a screening tool to identify women with OC at risk of LS.

Methods In this multicenter prospective cohort study, women with OC completed bHFQ, extended Family History Questionnaire (eFHQ; encompassing Amsterdam II criteria, Society of Gynecologic Oncology 20–25% criteria and Ontario Ministry of Health criteria), immunohistochemistry (IHC) for mismatch repair (MMR) proteins and universal germline testing for LS. Performance characteristics were compared between bFHQ, eFHQ, and IHC.

Results of 215 participants, 169 (79%) were evaluable with both bFHQ and germline mutation status; 12 of these 169 were confirmed to have LS (7%). Nine of 12 patients (75%) with LS were correctly identified by bFHQ, compared to 6 of 11 (55%) by eFHQ and 11 of 13 (85%) by IHC. The sensitivity, specificity, positive predictive values and negative predictive values of bFHQ were 75%, 66%, 15% and 98%. The 4-item bFHQ was more sensitive than eFHQ and took less than 10 minutes for each patient to complete.

Conclusions Patient-administered bFHQ may serve as an adequate screening tool to triage women with OC for further genetic assessment for LS, especially in centers without access to universal tumor testing for IHC for MMR.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.